Механизмы положительного действия статинов в комплексном лечении больных с хронической сердечной недостаточностью ишемической и неишемической этиологии
Диссертация
Среди основных причин развития ХСН по данным Euro Heart Survey Study, также как и Российского госпитального регистра ЭПОХА-О-ХСН, на долю ИБС приходится 60% случаев развития ХСН. Оставшиеся 40% принадлежат некоронарогенным заболеваниям сердца. Данные популяционных исследований последних лет (ADHERE), в том числе проводившихся в России (ЭПОХА-ХСН), демонстрируют нарастании вклада сахарного диабета… Читать ещё >
Содержание
- Оглавление
- Список сокращений
- Введение
- Глава I. ОБЗОР ЛИТЕРАТУРЫ
- 1. 1. История появления статинов
- 1. 2. Предпосылки использования статинов у больных ХСН ишемической этиологии
- 1. 3. Предпосылки использования статинов у больных ХСН неишемической этиологии
- 1. 4. Результаты ретроспективных анализов с применением статинов при ХСН
- 1. 5. Плейотропные эффекты статинов
- 1. 5. 1. Противовоспалительный и антицитокиновый эффекты статинов
- 1. 5. 2. Статины — нейрогормональные модуляторы
- 1. 5. 3. Способность миокардиального ремоделирования
- 1. 5. 4. Статины и эндотелиальная дисфункция
- 1. 5. 5. Теория неоангиогенеза и статины
- 1. 5. 6. Статины в регуляции автономной нервной системы
- 1. 5. 7. Антиаритмические возможности статинов
- 1. 5. 8. Исследования CORONA и GISSI-HF
- 1. 6. Возможное негативное влияние статинов на течение ХСН
- 1. 7. Побочные эффекты статинов
Список литературы
- Беленков Ю.Н., Мареев В. Ю., Агеев Ф. Т. Медикаментозные пути улучшения прогноза больных хронической сердечной недостаточностью. //Москва, «Инсайт», 1997.
- Lloyd-Jones DM, Larson MG, Leip ЕР, et al: Lifetime risk for developing congestive heart failure. The Framingham Heart Study. Circulation 2002- 106:3068−3072.
- Hunink MG, Goldman L, Tosteson AN, et al: The recent decline in mortality from coronary artery disease, 1980−1990. JAMA 1997- 277:535−542.
- Senni M, Tirboulloy CM, Rodeheffer RJ, et al: Congestive Heart Failure in the community: trends, incidence, and survival in a 10 year period. Arch Inter Med 1999- 159:29−34.
- Franciosa JA, Wilen М, Ziesch ES, Cohn JN: survival in men with severe chronic heart failure due to either coronary heart disease or idiopathic dilated cardiomyopathy. Am J Cardiol 1983- 51:831−836.
- Даниелян МО. Прогноз и лечение ХСН: данные 20-летнего ретроспективного наблюдения. Автореферат диссертации. 2001.
- Levy D., Kenchaiah S., Larson M. G., et al. Long-term trends in the incidence of and survival with heart failure. N Engl J Med 2002- 347:1887−1889.
- Ю.Н. Беленков, Ф. Т. Агеев. Эпидемиология и прогноз хронической сердечной недостаточности. РМЖ, 1999, т.7 № 2.
- Мареев В.Ю., Даниелян М. О., Беленков Ю. Н. Сравнительная характеристика больных с ХСН в зависимости от величины фракциивыброса по результатам Российского многоцентрового исследования ЭПОХА-О-ХСН. Сердечная недостаточность 2006−7(4): 164−171.
- Ю.Н. Беленков, И. В. Сергиенко, А. А. Лякишев, В. В. Кухарчук. Статины в современной кардиологической практике.
- Endo A., The discovery and development of HMG-CoA reductase inhibitors. Journal of Lipid Research Volume 33, 1992, 1569−1582.
- Endo A., Kuroda M., and Tanzawa K. Competitive inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase by ML-236A and ML 236B fungal metabolites, having hypocholesterolemic activity. FEBS Letters 1976- 72:323 326.
- Alberts A.W., Chen J., Kuron G., et al. Mevinolin: a highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and a cholesterol-lowering agent. Proc Natl. Acad Sci U.S.A 1980- 77:3957−3961.
- Yamamoto A., Sudo H., and Endo A. Therapeutic effects of ML-236B in primary hypercholesterolemia. Atherosclerosis 1980- 35:259−266.
- Сусеков A.B. «Ингибиторы ГМК-КоА-редуктазы при вторичной профилактике атеросклероза: 30 лет» Consilium medicum, том 7, № 11. 2005.
- Hanna IR, Heeke B, Bush H et al. Lipid-lowering drug use is associated with reduced preva lence of atrial fibrillation in patients with left ventricular systolic dysfunction. Heart Rhythm 2006- 3(8): 881−6.
- Franciosa JA, Wilen M, Ziesch ES, Cohn JN: survival in men with severe chronic heart failure due to either coronary heart disease or idiopathic dilated cardiomyopathy. Am J Cardiol 1983- 51:831−836.
- Петрухина А.А. Прогноз и лечение хронической сердечной недостаточности (данные 30-летнего наблюдения). Автореферат диссертации. 2008.
- Kjekshus J, Pedersen TR, Olsson AG, Faergeman O, Pyorala K. The effects of simvastatin on the incidence of heart failure in patients with coronary heart disease. J Card Fail. 1997−3:249−254.
- Aronow WS, Ahn C. Frequency of congestive heart failure in older persons with prior myocardial infarction and serum low-density lipoprotein cholesterol 125 mg/dl treated with statins versus no lipid lowering drug. Am J Cardiol. 2002−90:147−149.
- Ray JG, Gong YY, Sykora K, et al. Statin use and survival outcomes in elderly patients with heart failure. Arch Intern Med 2005- 165:62−67.
- Rammasubbu K. Report on HFSA meeting, Sep.2007.
- Sacks F.M., Pfeffer M.A., Moye L.A. et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N. Engl. J. Med., 1996, 335: 1001- 1009.
- Cannon CP, Braunwald E, McCabe CH et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004- 350: 1495−504.
- Kjekshus J, Apetrei E, Barrios V, et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med 2007−357:2248−2261.
- Braunwald E, Bristow MR: Congestive heart failure: fifty years of progress. Circulation 102: IV14, 2000.
- Liu HR, Zhao RR, Jiao XY, et al.: Relationship9f myocardial remodeling to the genesis of serum autoantibodies to cardiac beta 1-adrenoceptors and muscarinic type 2 acetylcholine receptors in rats. J Am Coll Cardiol 2002−39:1866.
- Baba A, Yoshikawa T, Ogawa S: Autoantibodies produced against sarcolemmal Na-K-ATPase: Possible upstream targets of arrhythmias and sudden death in patients with idiopathic dilated cardiomyopathy. Circulation 2002- 106:2448.
- Wallukat G, Reinke P, Dorffel WV, Luther HP, Bestvater K, Hofmann T, et al. Short-term hemodinamic effects of immunoadsorption and subsequent immunoglobulin substitution in dilated cardiomyopathy. Circulation 1997−54:191−195.
- Hanada T, Yoshimura A. Regulation of cytokine signaling and inflamation. Cytokine growth factor rev 2002- 13:413 21.
- Solar S, Mir MQ, Lerakis S, Tandon N, Khan BV. Atorvastatin improves left venricular systolic function and serum markers of inflammation in nonischemic heart failure. J Am Coll Cardiol 2006- 47: 332 7.
- Mozaffarian D, Minami E, Letterer RA, Lawler RL, McDonald GB, Levy WC. The effect of atorvastatin (10 mg) on systemic inflammation in heart failure. Am J Cardiol 2005- 96:1699 704.
- Node K., Fujita M., Kitakaze M. et al. Short-tern statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomiopathy. Circulation 2003- 108: 839 843.
- Segal R., Pitt B., Poole-Wilson P., Sharma D., Bradstreet D.C., Ikeda L.S. Effects of HMG-CoA reductase inhibitors (statins) in patients with heart failure. // Eur J Heart Fail. 2000- 2(Suppl 2): 96.
- Anker SD, Clark AL, Kilkowski C, et al. Statins and survival in 2068 CHF patients with ischemic and non-ischemic etiology. Circulation. 2002- 106 (suppl II): 2535.
- Horwich T., MacLellan W.R., Fonarow G. Statin therapy is associated with improved survival in ischemic and non-ischemic heart failure // J.Am.Coll.Cardiol.- 2004, — Vol.43, № 4, — P.642−648.
- Ray JG, Gong YY, Sykora K, et al. Statin use and survival outcomes in elderly patients with heart failure. Arch Intern Med 2005- 165:62−67.
- Jaganmoran S., Khurana V. Statins improve survival in patients with congestive heart failure: a study on 32 000 US veterans // J. Am. Coll. Cardiol. — 2005. — Vol. 45, Suppl. A. — P. 851−857.
- Thaik CM, Calderone A, Takahashi N, Colucci WS. Interleukin-1 beta modulates the growth and phenotype of neunatal rat cardiac myocytes. J Clin Invest 1995−96:1093.
- Krown Ka, Page MT, Nguyen C, et al Tumor necrosis factor alpha-induced apoptosis in cardiac myocytes: Involvement of the sphinfolipid sihnalin cascade in cardiac cell death. J Clin Invest 1996- 98:2854.
- Bozcurt B, Kribbs SB, Clubb FJ Jr, et al: Pathophysiologically relevant concentrations of tumor necrosis factor-alpha promote progressive left ventricular dysfunction and remodeling in rats. Corculation 1998- 97:1382.
- Libby P, Sukhova G, LeeRT, Galis ZS. Cytokines regulate vascular gunctions related to stability of the athrosclerotic plaque. J Cardiobase Pharmacol 1995−25 Suppl 2- S9−12.
- Saton M, Nakamura M, Akatru T et al. C-reactive protein co-expresses with cardiomyopathy. Eur J Heart Fail 2005−7(5):748−54.
- Timonen P, Magga J, Risteli Jetal. Cutokines interstitial collagen and ventricular remodelling in dilated cardiomyopathy. Int J Cardiol 2008- 124:3:293−300.
- Kanda T, Takahoshi J. Interleukin-6 and cardiovascular diseases. Jpn Heart J 2004−45:2:183−93.
- Abou-Shousha SA, Youssef Al. Interleukin-2 regulatory effect on P-selectin and interleukin-8 production in patients with chronic renal failure. //Egypt J Immunol. -2006.-Vol.13 (1).-P.ll-8.
- Panichi V, Taccola D, Rizza GM et al. Interleukin-8 is a powerful prognostic predictor of all-cause and cardiovascular mortality in dialytic patients. //Nephron Clin Pract. 2006, — Vol.102 (2).-P. c51−8.
- Sun Y, Schmitz JE, Acierno PM et al. Dysfunction of simian immunodeficiency virus/simian human immunodeficiency virus-induced IL-2 expression by central memory CD4+ T lymphocytes. //J Immunol. 2005.-Vol.174 (8). -P.4753−60.
- Kleeman R, Zadelaars S, Kooistra T. Citokines and atherosclerosis: a comprehensive review of studies in mice. Cardiovasc Res 2008−79(3):360−76.
- Yamaoka-Tojo M, Inomata T et al/ Circulating levels of interleukin-18 reflects ethiologies of heart failure: Thl/Th2 cytokines imbalance exaggerates the pathophysiology of advanced heart failure. J Cardiol Fail 2002- vol 8(1)-21 -7.
- Wang M, Marke 1 TA, Meldrum DR. Interleukin-18 in the heart. Shock 2008- Vol 30(1) 3−10.
- Eslick GD, ThampanBV, Nalos M et al. Circulating interleukin-18concentrations and a loss-of-function P2X7 polimorpgism in heart failure. Int J Cardiol 2008 Aug 2 Epub ahead of print.
- Isaack A., Lindenmann J. Virus interference. I. The Interferon // Proc. Roy. Soc. Series B. — 1957. — Vol. 147. — P. 258−267.
- Limas C. J, Hasikidis C, Iakovou J et al. Prognostic significance of soluble interleukin-2 receptor levels in patients with dilated cardiomyopathy.//Eur J Clin Invest.- 2003. Vol.33(6). P.443−8.
- Munger M. A, Johnson B, Amber I. J et al. Circulating concentrations of proinflammatory cytokines in mild or moderate heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. //Am J Cardiol.- 1996. Vol. 77(9). P.723−7.
- Koller-Strametz J, Pacher R, Frey B, Kos T et al. Circulating tumor necrosis factor-alpha levels in chronic heart failure: relation to its soluble receptor II, interleukin-6, and neurohumoral variables. J Heart Lung Transplant. 1998- 17(4):356−62.
- Bevilacqua MP. Endothelial-leukocyte adhesion molecules. Annu Rev Immunol 1993- 11:767−804.
- Tousoulis D, Antoniades C, Vassiliadou C et al. Effects of combined administration of low dose atorvastatin and vitamin E on inflammatorymarkers and endothelial function in patients with heart failure. Eur J Heart Fail 2005−7:1126−32.
- Chung HK, Lee IK, Kang H, et al. Statin inhibits interferon-gammma-induced expression of intercellular adhesion molecule-1 (ICAM-1) in vascular endothelial and smooth muscle cells. Exp Mol Med 2002- 34:451 -61.
- Kwak B, Mulhaupt F, Myit S, Mach F. Statins as a newly recognized type of immunomodulator. Nat Med 2000−6:1399 402.
- Saijonmaa O, Nyman T, Stewen P, Fyhrquist F. Atorvastatin completely inhibits VEGF-induces ACE upregulation in human endothelial cells. Am J Physiol Heart Circ Physiol 2004−286:H2096 102.
- Ito M, Adachi T, Pimentel DR, Ido Y, Colucci WS. Statins inhibit beta-adrenergic receptor-stimalated apoptosis in adult rat ventricular myocytes via a Racl-dependent mechanism. Circulation 2004- 110:412 8.
- Romano S, Necozione S, Guarracini L et al. Accuracy of N-terminal pro-brain natriuretic peptide in the identification of left ventricular dysfunction in high-risk asymptomatic patients.//J Cardiovasc Med (Hagerstown). 2009- 10(3):238−44.
- Ю.Н.Беленков, В. Ю. Мареев Принципы рационального лечения сердечной недостаточности. 2000 «Медиа Медика».
- Hattori Т, Shimokawa Н, Higashi М, et al. Long-term inhibition of Rho-kinase suppresses left ventricular remodeling after myocardial infarction in mice. Circulation 2004- 109:2234 9.
- Martin J, Denver R, Bailey M, Krum H. In vitro inhibitory effects of atorvastatin on cardiac fibroblasts: implications for ventricular remodeling. Clin Exp Pharmacol Physil 2005−32:697 701.
- Martin J, Denver R, Bailey M, Krum H. In vitro inhibitory effects of atorvastatin on cardiac fibroblasts: implications for ventricular remodeling. Clin Exp Pharmacol Physil 2005−32:697 701.
- Zaca V, Rastogi S, Imai M, et al. Chronic monotherapy with rosuvastatin prevents progressive left ventricular dysfunction and remodeling in dogs with heart failure. J Am Coll Cardiol. 2007−50:551−7.
- Furchgott RF., Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980- 288: 373 376.
- Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002- 105:1135 -43.
- Paolo С. Colombo, Duygu Onat, Hani N Sabban. Acute heart failure as «acute endothelitis» interaction of fluid overload and endothelial dysfunction. E J of Heart Failure 2008- 10:170- 175.
- Virdis A, Neves MF, Amiri F, Viel E, Touyz RM, Schiffrin EL: Spironolactone improves angiotensine-induced vascular changes and oxidative stress. Hypertension, 2002, 40, 504 510.
- Bauersachs J, Fraccarollo D: Endothelial NO synthase target of aldosterone. Hypertension, 2006, 48, 27 28.
- Takeda Y, Miyamori I, Yoneda T, Hatakeyama H, Inaba S, Furukawa K, Mabuchi H et al.: Regulation of aldosterone synthase in human vascular endothelial cells by angiotensin II and adrenocorticotropin. J Clin Endocrinol Metab, 1996,81,2797−2800.
- Cardillo C, Campia U, Kilcoyne CM, et al. improved endothelium-dependent vasodilation after blockade of endothelin receptors in patients with essential hypertension. Circulation 2002- 105:452−56.
- Aronson D, Burger AJ. Neurohormonal prediction of mortality, following admission to decompensated heart failure. Am J Card 2003- 91:245 8.
- Leung WH, Lau CP, Wong CK. Beneficial effects of cholesterol-lowering therapy on coronary endothelium-dependent relaxation in hypercholesterolemic patients. Lancet 1993- 341: 1496 500.
- Laufs U, La Fata V, Plutzky J, et al. Upregulation of endothelial nitric oxide synlhase by HMG CoA reductase inhibitors. Circulation 1998−97: 1129−35.
- Anversa P, Ricci R, Olivetti G. Effects of exercise on the capillary vasculature of the rat heart. Circulation 1987−75:112−8.
- Anversa P, Beghi C, Kikkawa Y, Olivetti G. Myocardial infarction in rats. Infarct size, myocyte hypertrophy, and capillary growth. Circ Res 1986- 58:26 -37.
- Kureishi Y, Luo Z, Shiojima I, et al. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med 2000−6:1004−10.
- Michowitz Y, Goldstein E, Wexler D, Sheps D, Keren D, Gearge J. Circulating endothelial progenitor cells and clinical outcome in patients with congestive heart failure. Heart 2007−93:1046 50.
- Dimmeler S, Aicher A, Vasa m, et al. HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI 3-kinase/Akt pathway. J Clin Invest 2001- 108:391 -7.
- Rundqvist B, Elam M, Bergman-Sverrisdottir Y, et al: Increased cardiac agrenergic drive precedes generalized sympathetic activation in human heart failure. Circulation 1997−95:169−175.
- Cohn J., Levine T., Olivari M., et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 1984−311:819−23.
- Gao L, Wang W, Li YL, et al. Simvastatin Therapy Normalizes Sympathetic Neural Control in Experimental Heart Failure. Roles of Angiotensin II Type 1 Receptors and NAD (P)H Oxidase. Circulation. 2005 Sep 12.
- Vrtovec B, Okrajsek R, Golicnik A, Ferjan M, Stare V, Radovancevic B. Atorvastatin therapy increases QT variability, and shortens QTc interval duration in patients with advanced chronic heart failure. J Card Fail 2005- 11:684−90.
- Mitchell LB, Powell JL, Gillis AM, Kehl V, et al. Are lipid-lowering drugs also antiarrhythmic drugs? An analysis of the Antiarrhythmics Versus Implantable Defibrillators (AVID) trial J Am Coll Cardiol 2003−42:81−87.
- Young-Xu Y, Jabbour S, Goldberg R, et al «Usefulness of statin drugs in protecting against atrial fibrillation in patients with coronary artery disease». Am J Cardiol 2003−92:1379−1383.
- Hanna IR, Heeke B, Bush H et al. Lipid-lower ing drug use is associated with reduced preva lence of atrial fibrillation in patients with left ventricular systolic dysfunction. Heart Rhythm 2006- 3(8): 881−6.
- Patti G, Chello M, Candura D et al. Random ized Trial of Atorvastatin for Reduction of Post operative Atrial Fibrillation in Patients Undergo ing Cardiac Surgery. Circulation 2006- 114: 1455−61.
- Niebauer J., Volk HD, Kemp M, Dominguez M, Schumann RR, Rauchhaus M, et al. Endotoxin and immune activation in chronic heart failure: a prospective cohort study. Lancet 1999- 97:1366 72.
- Арутюнов Г. П. Гиполипидемическая терапия у больных с ХСН. Кому? Когда? Чем? Сердечная недостаточность, 2006, 4−4.
- Rundek Т, Naili A, Sacco R, Coates К, DiMauro S. Atorvastatin decreases the coenzyme Q 10 level in the blood of patients at high risk for cardiovascular disease and stroke. Arch Neurol 2004- 61: 889 92.
- Turunen M, Olsson J, Dallner G. Metabolism and function of coenzyn Q. Biochim Biophys Acta 2004- 1660:171 -99.
- Warner GJ, Berry MJ, Moustafa ME, Carlson В A, Hatfield DL, Faust JR. Inhibition of selenoprotein synthesis by selenocysteine tRNA Sec lacking isopentenyladenosine. J Bio Chem 2000- 275:28 110−9.
- Angulo P. Nonalcoholic fatty liver disease. N Engl J Med (2002) 346:1221−31.
- Chua D, Tsang RS, Kuo IF. The role of statin therapy in sepsis. Ann Pharmacother (2007) 41:647−52.
- ТВ Horwich et al. Low serum total cholesterol is associated with marked increase in mortality in advanced heart failure. J Card Fail 2002 8: 216−224.
- Anker SD, Clark AL, Winkler R, et al. Statin use and survival in patients with chronic heart failure-results from two observational studies with 5200 patients. Int J Cardiol. 2006- 112:234−242.
- Шахиджанова С.В. Оценка структурно-функционального состояния печени у больных с хронической недостаточностью кровообращения. Дис.Канд. мед.наук. М.1992.С.163.
- Leeper NJ, Ardehali R, deGoma EM, Heidenreich PA. Statin use in patients with extremely low low-density lipoprotein levels is associated with improved survival. Circulation. 2007−116:613−618.
- Sumner, A.D., Boehmer J., Saxon L.A. et al., Statins use is associated with a marked improvement in survival in an advanced heart failure populationfrom the COMPANION trial. //J. Am. Coll.Cardiol. 2005 — vol.45, Suppl. A -p.851 — 858.
- Kjekshus J, Apetrei E, Barrios V, et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med 2007−357:2248−2261.
- Paula K. Lorgelly, Andrew H. Briggs, Hans Wedel An economic evaluation of rosuvastatin treatment in systolic heart failure: evidence from the CORONA trial. European Journal of Heart Failure (2010) 12, 66−74.
- Buller N.P., Jones D.A., Poole-Wilson P.A. Direct measurement of skeletal muscle fatique in patient with chronic heart failure. Br Heart J. 1991- 65: 20−24.
- Minotti J.R., Christoph 1., Oka R., et al. Impaired skeletal muscle function in patients with congestive heart failure. J Clin Invest 1991- 88:20 772 082.
- Duscha B.D., Kraus W.E., Keteyian S.J., et al. Capillary density of skeletal muscle: a contributing mechanism for exercise intolerance in class II-III chronic heart failure her peripheral alterations. J Am Coll Cardiol. 1999- 33(7): 1956−63.
- Wilson JR. Evaluation of skeletal muscle fatigue in patients with chronic heart failure. J Mol. Cell. Cardiol. 1996- 28(1): 2287−92.
- McAllister R.M., Laughlin M.H., Musch T.I. Effects of chronic heart failure on skeletal muscle vascular transport capacity of rats. Am J Physiol 1993- 264(3Pt2): H689−91.
- Gurgun C. et al. The effects of short term statin treatment on left ventricular function and inflammatory markers in patients with chronic heart failure. Int J Cardiol 2008 Jan 11- 123(2): 102−7.
- Nickenig G, Baumer AT, Temur Y, Kebben D, Jockenhovel F, Bohm M. Statin-senditive dysregulated ATI receptor function and density in hypercholesterolemic men. Circulation 1999- 100:2131 -4.
- Horiuchi M, Cui TX, Li Z, Li JM, Nakagami H, Iwai M. Fluvastatin enhances the inhibitory effect of a selective angiotensin II type 1 receptor blocker, valsartan, on vascular neointimal formation. Circulation 2003−107:106 12.
- Dimmeler S, Fleming I, Fisslthaler B, Hermann C, Busse R, Zeiher AM. Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorilation. Nature 1999−399:601 -7.
- Sun W, Lee IS, Zhu M, et al. Statins activate AMP-activated protein kinase in vitro and in vivo. Circulation 2006- 114:2655 62. 2. Rikitake Y, Liao JK. Rho GTPases, statins, and nitric oxide. Circ Res 2005−97:1232 — 5.
- Bonetti PO, Wilson SH, Rodriguez-Porcel M, et al. Simvastatin preserves myocardial perfusion and coronary microvascular permeability in experimental hypercholesterolemia independent of lipid lowering. J Am Coll Cardiol 2002−40:546−54.
- Tousoulis D, Antoniades C, Vassiliadou C, et al. Effects of combined administration of low dose atorvastatin and vitamin E on inflammmatoru markers and endothelial function in patients with heart failure. Eur J Heart Fail 2005−7:1126−32.
- Verma S, Wang CH, Li SH, et al.: A self fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation, 2002, 106:913 9.
- Reduction in Blood Pressure With Statins. Results From the UCSD Statin Study, a Randomized Trial. Beatrice A. Golomb, MD, PhD- Joel E. Dimsdale, Arch Intern Med. 2008- 168(7):721−727.
- Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. //The Lancet 4 October 2008- Volume 372, Issue 9645: Page 1231.
- Татенкулова C.H. Изучение иммунореактивности при хронической сердечной недостаточности различной этиологии и возможности иммунокоррекции статинами. Автореферат диссертации. 2009.
- Волкова С.Ю. «Клинико-прогностические аспекты оценки мозгового натрийуретического пептида и провоспалительных цитокинов у больных ишемической болезнью сердца. Автореферат диссертации. 2009.
- Young-Xu Y, Jabbour S, Goldberg R, et al «Usefulness of statin drugs in protecting against atrial fibrillation in patients with coronary artery disease». Am J Cardiol 2003−92:1379−1383.
- J.org Stypmann, Aurelien Schubert, Henryk Welp. Atorvastatin Therapy Is Associated with Reduced Levels of N-terminal Prohormone Brain
- Natriuretic Peptide and Improved Cardiac Function in Patients with Heart Failure. Clin. Cardiol. 2008, 31,10, 478−481.
- Szramka M, Harriss L, Ninnio D et al (2007) The effect of rapid lipid lowering with atorvastatin on autonomic parameters in patients with coronary artery disease. Int J Cardiol 117(2):287−291.
- Сычев А.В. Влияние стандартной терапии в сочетании с пентоксифиллином на клинический статус, активность нейрогормональных систем и жизнеспособность миокарда у больных с хронической сердечной недостаточностью. Автореферат диссертации 2010.
- Notarius, С. F., Atchison, D. J., & Floras, J. S. (2001). Impact of heart failure and exercise capacity on sympathetic response to handgrip exercise. Am J Physiol, 280, H969-H976.
- Middlekauff, H. R., Chiu, J., Hamilton, M. A., et al. (2004). Muscle mechanoreceptor sensitivity in heart failure. Am J Physiol, 287, HI 937-H1943.
- Houghton AR, Harrison M, Cowley AG, Hampton JR. Assessing exercise capacity, quality of life and haemodynamics in heart failure: do the tests tell us the same thing? Eur J Heart Fail 2002−4:289−295.